Drugs in Dev. Oncology
Discovery
Switzerland 
Details : The collaboration aims to develop and commercialize DARPin in the radioligand therapy field. The parties will collaborate in discovery, candidate selection and preclinical development of Athebody® DARPins for use as Radio-DARPin drug entities.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 18, 2023
Details : Under the collaboration, the companies will focus on the discovery and development of small molecules targeting an undisclosed and novel cancer-focused G protein-coupled receptor (GPCR).
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 17, 2023
LegoChemBio Signs License Agreement to Acquire First-in-class Antibody From Elthera
Details : Under the terms of the licensing agreement, LegoChem Biosciences will develop and commercialize a novel antibody-drug conjugate (ADC) therapy using a monoclonal antibody developed by Elthera.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
February 13, 2023
Details : The proceeds will be used to develop novel fragile-X mental retardation protein (FMRP) inhibitors in oncology as well as a diverse portfolio of clinical and preclinical oncology programs acquired from Plexxikon Inc.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 21, 2022
Details : Debiopharm Innovation Fund strategically invests in Whitelab Genomics’ mission to make genomic medicine development faster and leaner for more efficient access to cancer patients in the future.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 13, 2022
Nodus Oncology Announces Acquisition of Basilea Pharmaceutica’s PARG Inhibitor Programme
Details : Nodus secures worldwide development and commercialization rights to Basilea’s PARG inhibitor (PARGi) programme – currently at the discovery stage - which has the potential to be a best-in-class treatment for molecularly defined patient sub-groups.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 09, 2022
Basilea Announces Sale of Preclinical Oncology Program to Nodus Oncology
Details : Under the terms of the agreement, Basilea entered into an asset purchase agreement with Nodus Oncology for Basilea’s novel poly (ADP-ribose) glycohydrolase (PARG) inhibitor discovery program.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 09, 2022
Araris Biotech Closes $24 Million Financing Round
Details : Proceeds from the financing will be used to support the further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates, created using the Company’s proprietary linker technology, as Araris moves closer towards clinical develo...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 10, 2022
Details : Proceeds from the financing will be used to further build Engimmune’s pipeline having T-cell receptor based therapies, expand the research team in Switzerland, with a focus on GMP-certified manufacturing, clinical development, and regulatory affairs.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 05, 2022
Details : Under the terms of the agreement, MTx will leverage its best-in-class microfluidic single-cell molecular cloning and screening technologies to discover antibodies for immuno-oncology targets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 11, 2022
Reset All
